Law & Admin Flashcards
What are the legal duties of the commercial QP and where to find?
As referenced in Statutory instrument 2012/1916 Sch. 7 Pt. 3.
The GB QP must ensure that:
- The batch has been m&t iaw NATIONAL LAW and the requirements of the MA.
- IMPORTED product from countries NOT on the ‘countries approved for import list’ have been tested for FULL
QUALITATIVE ANALYSIS, and QUANTITATIVE ANALYSIS at least the ACTIVE SUBSTANCES,
- All SAFETY FEATURES are affixed to packaging as per market requirements.
- Certification is RECORDED IN REGISTER or equivalent.
What are the non-delegable duties?
- Certification is permitted under the terms of the MIA
- Additional responsibilities and duties of National
Legislation have been complied with. - Certification is recorded in a register or equivalent.
Legal Duties of the IMP QP and where to find?
UKSI 2004/1031 Part 6 section 43
The GB IMP QP must ensure that:
- The batch has been manufactured and checked in
accordance with GMP, and the PSF, and in compliance with the authorisation in place (for
example, a CTA).
- Imported product has been manufactured and tested in
accordance with GMP or equivalent,
- Imported comparators have been manufactured In
accordance with GMP or equivalent or tested,
- Certification is recorded in a register or equivalent.
Delegable duties
- GMP has been complied with.
- The entire supply chain is documented, available to the QP,
preferability in the format of a comprehensive diagram. - All sites involved in the manufacture and testing of the
product and manufacture of the API have been audited and the
audit reports available to the QP. - All sites of manufacture, analysis and certification comply
with the terms of the MA. - All manufacturing activities and testing activities are
consistent with the MA. - The source and specification of all starting materials and
packaging materials comply with the MA, and a supplier
quality management system is in place. - All APIs used have been manufactured in accordance with
GMP and where relevant, distributed in accordance with GDP. - Imported APIs for human medicines comply with the
falsified medicines directive requirements, i.e. a written
confirmation of GMP compliance from countries not on the
white list. - Human medicines excipients used have been manufactured
in accordance with an appropriate level of GMP. - Where relevant, the TSE status of all materials complies
with the MA. - All records are complete and endorsed by appropriate
personnel. All in process controls and checks are complete. - All manufacturing and testing processes remain in the
validated state. Personnel are trained or qualified where
required. - QC data continues to meet the registered specification, or
where authorised, the Real Time Release Testing programme. - All post marketing commitments have been addressed.
The ongoing stability data continues to support certification. - The impact of any change to product manufacture or
testing has been evaluated and any additional checks and tests
are complete. - Any investigations pertaining to the batch in question have
been completed to a sufficient level to support certification. - All ongoing complaints, investigations and recalls do not
negate the conditions for certification of the batch in question. - All required technical agreements are in place.
- The self-inspection programme is current and active.
- Appropriate arrangements are in place for distribution and
shipping. - Product for the EU market has the required safety features.
How are they different commercial vs IMP QP?
QP Viva Flashcard: Commercial vs IMP Responsibilities
- Legislation & Licence
• Commercial:
• SI 2012/1916 – Human Medicines Regulations
• Requires MIA (Manufacturer’s Licence)
• IMP:
• SI 2004/1031 – Clinical Trial Regulations
• Requires MIA(IMP) licence
⸻
- Basis for Batch Certification
• Commercial:
• Complies with Marketing Authorisation (MA)
• IMP:
• Complies with CTA, IMPD, and Product Specification File (PSF)
⸻
- Documentation
• Commercial:
• QP certification logged in register
• IMP:
• QP issues formal batch certificate (filed in Trial Master File)
⸻
- Release Process
• Commercial:
• Single-step release: QP certification → batch can be sold
• IMP:
• Two-step release:- QP certification
- Sponsor’s regulatory release (after ethics & CTA approvals)
⸻
- GMP Requirements (Sliding Scale)
• Commercial:
• Full validation of process & methods expected
• IMP:
• Phase-appropriate GMP
• Early phases: limited validation allowed (risk-based)
⸻
- Packaging & Labelling
• Commercial:
• Follows MA-approved pack & label
• IMP:
• Must meet Annex 13
• Includes trial-specific info, expiry, blinding, etc.
⸻
- Comparators / Placebos
• Commercial:
• Not applicable
• IMP:
• QP ensures quality & traceability of comparators, placebos, rescue meds
• May require testing or repackaging under GMP
⸻
- Regulatory Changes
• Commercial:
• Release only if MA variation approved
• IMP:
• Confirm CTA amendments or PSF updates are approved before release
What regal duties of VET QP?
UKSI 2013/2033
The VET QP ensure that
- Each batch batch is manufactured in compliance with GMP and tested in compliance with the terms of the MA.
- Certification recoded as register and draw up a control report.
- Ensure each imported (out side of CERS: countries with Equivalent Regulatory Standards) batch has undergone full qualitative and quantitative analysis of at least all the active substances, and all the other tests necessary.
Are you aware of any recent legislation changes in the UK?
- Windsor Framework
- Point of Care - Modular Manufacturing
- Changes to Clinical Trials regulations
- Veterinary medicine legislation 2013/2033 update
- International Recognition Procedure
What is WF?
- Ensure the smooth flow of POM medicines between GB and NI while protecting the EU single market
- by ‘UK only’ label (grace period by June 25)
- MHRA has become independent competent authority in the UK including NI
- FMD repealed
WF - please talk about product categories, licence changed, packaging material?
- Product Categories (Law & Admin)
Under the Windsor Framework, medicines supplied in Northern Ireland (NI) are permanently regulated by the MHRA, and not the EMA, which is a key divergence from the original Northern Ireland Protocol. This change applies to:
• Human Medicines, including Prescription-only (POM), Pharmacy (P), and General Sales List (GSL).
• Biological products and ATMPs—included within the MHRA’s scope for NI. - Licensing
Previously, products supplied to NI had to follow EU centralised or mutual recognition procedures. Now, under the Windsor Framework:
• UK-wide licences (PL) apply to NI too.
• The MHRA is the sole licensing authority for GB and NI.
• This simplifies QP responsibilities—one licence, one regulator. - Packaging Materials (Pharmaceutical Packaging – QP Study Guide Section i)
• All packs for UK (GB and NI) must now carry the “UK Only” label.
• The Falsified Medicines Directive (FMD) no longer applies in NI—so no 2D barcode or anti-tampering device is required for UK-only packs.
• For a transition period, stickers stating “UK Only” are permitted.
Packaging control expectations for the QP include:
• Ensuring packaging and labelling changes (e.g., “UK Only”) are reflected in the approved MA and artwork approval systems.
• Oversight of line clearance, reconciliation, and visual/automated checks to prevent pack mix-ups (as per QP Study Guide).
• Managing change control for printed component updates and revalidations as needed.
Whether WF applied to veterinary products and where would you check to find?
- WF apply to human medicines
- can check via:
MHRA guidance, VMD website
What is POC and modular manufacturing?
- draft 2025 legislation
- Regulation 2025/87
- Scope: Short shelf-life human meds (e.g. ATMPs)
- Purpose: Flexibility in ATMP manufacturing
- Model: Hub (MIA, MIA/IMP, MA) + Bespoke sites (e.g. hospitals)
- Controlled by:
Decentralised Manufacturing Master File (DMMF)
Pharmacovigilance
What is the role of EDQM?
- A directorate of the COUNCIL of EUROPE, NOT for the EU (located in Strasbourg, FRA)
- European Pharmacopoeia: Developing and maintaining quality standards for medicines and substances.
- CEP Certification (Certificate of Suitability to the Monographs of the Ph. Eur.): Used to demonstrate API compliance with the Ph. Eur.
- OMCL Network: Coordinates a network of Official Medicines Control Laboratories for independent medicine testing.
- Also involved in blood transfusion, organ transplantation, cosmetics, and healthcare standards.
What is the role of ICH?
- The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
- Harmonising Guidelines of drug registration (regal enforcement when adopted)
- Members (over 50)
Founding regulatory/ industry members (EU, US, Japan)
Standing regulatory members
Regulatory/ industry members
Observers (e.g. WHO)
What ICH guidelines are there?
Q -Quality
Product development, GMP, PQS
S - Safety
Preclinical toxicology
E - Efficacy
Clinical trial design and conduct
M - Multidisciplinary
Cross-cutting tools (e.g. CTD, digital standards)
What are the implementation steps in ICH guidelines?
Step 1 – Consensus Building
•Expert Working Group (EWG) is formed with experts from ICH members.
•They draft the guideline and reach scientific consensus on the technical content.
•Once agreed, the draft is submitted to the ICH Management Committee.
Step 2 – Confirmation of Consensus & Drafting for Public Consultation
•The ICH Assembly confirms that consensus has been reached.
•The guideline is now considered a Step 2 document.
•It is released for regional public consultation (e.g. in the EU, US, Japan).
Step 3 – Regulatory Consultation & Discussion
•Each ICH region conducts public consultation.
•Comments are collected, reviewed, and incorporated by the EWG.
•The EWG works to resolve any issues raised and finalises the text.
•Once consensus is reached again, it becomes a Step 3 document.
Step 4 – Adoption of Harmonised Guideline
•The ICH Assembly formally adopts the harmonised guideline.
•It now becomes an official ICH Guideline.
Step 5 – Implementation
•Each regulatory authority (e.g. FDA, EMA, PMDA) implements the guideline according to their local procedures.
•This could involve integration into legislation, regulatory expectations, or guidance documents.
What are the current updates of ICH guidelines?
- ICH Q2(R2) & ICH Q14 – Finalized (Step 4) in November 2023
Q2(R2): Revision of the guideline on Analytical Validation. It now includes:
-Integration with ICH Q14 (Analytical Procedure Development)
- Expanded scope (R1 is just for GC and HPLC) to include multivariate and complex analytical procedures (NIR, Raman spectroscopy)
*Clarity on validation of methods developed using QbD and PAT principles.
-Annexes with Examples
Q2(R2) includes Annex 1 and 2:
Annex 1: Selection of validation tests depending on method type and purpose.
Annex 2: Illustrative validation examples for different analytical techniques (e.g., HPLC, GC, ELISA).
Q14: A brand-new guideline on Analytical Procedure Development, promoting:
*A lifecycle approach.
*Risk-based method development.
*Flexibility in regulatory submissions by supporting structured method development.
- ICH E19 – Finalized (Step 4)
*E19: Focuses on Optimization of Safety Data Collection in late-stage pre-approval clinical trials.
*Allows targeted safety data collection in specific situations, minimizing unnecessary burden on trial sites while maintaining patient safety.
*Useful in trials where safety profile is well understood. - ICH M11 – Ongoing (Step 2 in 2023, progressing)
*M11: Clinical electronic Structured Harmonized Protocol (CeSHarP).
*Aims to standardize the format and content of clinical trial protocols.
*Will make trial design and submission more interoperable and efficient. - ICH E6(R3) – Draft (Step 2 in May 2023)
*A major overhaul of Good Clinical Practice (GCP) guidelines.
*Emphasis on risk-based, proportionate approaches.
*Modernization to accommodate digital trials, decentralized approaches, and new tech.
What is the role of PIC/S?
- Pharmaceutical Inspection Co-operation Scheme
- Participants 56 countries including the MHRA (UK), FDA (US), PMDA/PMDA-OMI (Japan), TGA (Australia), and most EU member states.
- Harmonising GMP inspection procedure worldwide.
- NON REGAL ENFORCEMENT
Are you aware of any recent legislation changes in the EU?
- EU Clinical Trials Regulation (CTR 536/2014)
*Centralised EU clinical trial applications now submitted via the CTIS portal.
*Replaces Directive 2001/20/EC. - EU GMP Annex 1 Revision (Sterile Medicinal Products)
*Introduces stricter requirements for Contamination Control Strategy, visual inspection, PUPSIT, and cleanroom classification. - EU Pharmaceutical Legislation Reform – Revision of Directive 2001/83/EC
*Still under discussion in 2025.
*Focuses on access to medicines, incentives, AMR, and regulatory simplification. - EU Artificial Intelligence (AI) Act
*Risk-based classification of AI systems, including potential applications in automated GMP systems.
*Relevant to data integrity, AI-assisted decision-making, and GxP software. - EU Packaging and Packaging Waste Regulation (PPWR)
*Will set new rules on packaging design, labelling, reuse, and waste reduction.
*May affect secondary/tertiary pharma packaging, especially in relation to tamper-evidence and sustainability goals.
Are you aware of any recent GMP changes in the EU?
- Annex 1 – Sterile Medicinal Products
•Fully revised and came into effect August 2023, with a transitional period until August 2024 for certain elements (e.g. CCS and lyophiliser loading).
•Strengthens expectations around contamination control strategy, PUPSIT, QRM, cleanroom classification, and visual inspection — all directly relevant to aseptic and radiopharmaceutical production. - Annex 21 – Importation of Medicinal Products
•Clarifies requirements for imports from non-MRA countries, including supply chain traceability, documentation, and site oversight. - Implementation of ICH Q12, Q13, and Q14
•Adopted into EU GMP:
•Q12: Lifecycle management and change control.
•Q13: Continuous manufacturing.
•Q14: Analytical procedure development (alongside revised Q2 on method validation). - Annex 3 – Manufacture of Radiopharmaceuticals
•Still in force but due for revision.
•A draft revision is anticipated to align Annex 3 with the principles of revised Annex 1, especially for aseptic radiopharmacies and short-shelf-life products. - Annex 4 (Veterinary Medicinal Products) and Annex 5 (Immunological VMPs)
•Updates are underway, currently in draft or consultation phase.
•Intended to align veterinary GMP with recent updates in human GMP, and with EU Regulation (EU) 2019/6 on veterinary medicinal products.
What are expected changes in up coming UK CT regulation update?
- Legislative Update
•The current legislation is based on SI 2004/1031, which implemented the old EU Clinical Trials Directive (2001/20/EC).
•The new UK clinical trials framework will replace this, aiming to be more flexible, efficient, and supportive of innovation. - Risk-Proportionate Approach
•Clinical trials will be regulated based on the risk to participants rather than a one-size-fits-all model.
•Enables more streamlined requirements for low-intervention trials, supporting academic and early-phase research. - Simplified Application Process
•A combined regulatory and ethics review will be introduced, led by the MHRA in collaboration with the Health Research Authority (HRA).
•Expected to significantly reduce start-up timelines. - Greater Use of Digital and Decentralised Trials
•The new framework supports remote monitoring, e-consent, and digital data capture, aligning with modern trial conduct practices. - Transparency and Public Involvement
•Sponsors will be required to register trials, publish results, and involve patients more actively in trial design and conduct. - Alignment with International Standards
•The UK aims to remain globally competitive, so the new rules will align with ICH GCP (R3) and support mutual recognition where possible, while still being independent of the EU CTR.
Are you aware of recent VET regulation update?
Under new requirement, QP must ensure the quality of returned veterinary medicines following a recall:
*Veterinary QPs must carry out a documented risk assessment before any returned product is considered for resale.
*The QP must ensure the returned stock was stored in line with conditions described in the SmPC, and there must be no confusion or risk of mix-up.
*If these criteria aren’t met, the returned product must not be returned to the market.
Can you discuss some of the key Primary Legislations relevant to medicinal Products in the UK?
Medicines Act 1968
•This is the foundational legislation for the control of medicines in the UK.
misuse medicines act 1972
Can you explain the differences with Secondary legislation?
Primary legislation
Acts of Parliament
- Sets legal framework
- Passed by Parliament
- Example: Medicines Act1968
Secondary legislation
- Also called delegated/subordinate legislation
- Made under authority of primary legislation
- Provides detailed rules
- Made by Ministers or regulatory bodies
- Quicker to amend
- Example: Statutory Instruments (SIs) like Human Medicines (Amendment) Regs
The role, legal status, and structure of both the British and European Pharmacopoeias,
British & European Pharmacopoeias
Role:
- Provide official standards for the quality of medicines and substances.
- Used for QC testing, release, and regulatory compliance.
Legal Status:
BP:
- Legal standard in the UK, under HMR 2012.
- Mandatory for licensed medicines in the UK.
Ph. Eur.:
- Legal in all Council of Europe countries.
- Binding in EU and UK (post-Brexit, UK still adopts it unless diverged).
Structure - Volume 1-5 + Vet BP:
1 & 2 - Monograph for Medicinal Substances
3 - General and Specific Monograph for FORMULATED preparations
4 - Herbal, Blood, Immunological, Radio pharmaceutical products
5 - Infrared Reference Spectra, Appendices ( Analytical methods, microbiology, sterility, etc)
6 - Vet pharmacopoeia